blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3193869

EP3193869 - PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  19.02.2021
Database last updated on 24.08.2024
FormerExamination is in progress
Status updated on  31.08.2018
FormerRequest for examination was made
Status updated on  23.06.2017
FormerThe international publication has been made
Status updated on  24.02.2017
Most recent event   Tooltip19.02.2021Refusal of applicationpublished on 24.03.2021  [2021/12]
Applicant(s)For all designated states
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Ludwig-Erhard-Allee 2
53175 Bonn / DE
For all designated states
Klinikum rechts der Isar der Technischen Universität München
Ismaninger Straße 22
81675 München / DE
[2017/30]
Inventor(s)01 / HÖGLINGER, Günter
Egenhofenstraße 1e
82152 Planegg / DE
02 / BRUCH, Julius
Zittelstraße 5
80796 München / DE
03 / RÖSLER, Thomas
Irmonherstraße 6
81241 München / DE
 [2017/30]
Representative(s)Gosmann, Martin, et al
Gospat-Patentanwalt
Schlägerstraße 23
30171 Hannover / DE
[2017/30]
Application number, filing date15762491.714.08.2015
[2017/30]
WO2015EP68734
Priority number, dateEP2014018107114.08.2014         Original published format: EP 14181071
[2017/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016024010
Date:18.02.2016
Language:EN
[2016/07]
Type: A1 Application with search report 
No.:EP3193869
Date:26.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 18.02.2016 takes the place of the publication of the European patent application.
[2017/30]
Search report(s)International search report - published on:EP18.02.2016
ClassificationIPC:A61K31/4704, A61P25/28
[2017/30]
CPC:
A61K31/195 (EP,US); A61K31/415 (EP,US); A61K31/4152 (EP,US);
A61K31/42 (EP,US); A61K31/4704 (EP,US); A61K31/4709 (EP,US);
A61P25/28 (EP); A61K31/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/30]
TitleGerman:PERK-AKTIVATOR ZUR BEHANDLUNG NEURODEGENERATIVER ERKRANKUNGEN[2017/30]
English:PERK ACTIVATOR FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES[2017/30]
French:ACTIVATEUR DU SIGNAL PERK POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES[2017/30]
Entry into regional phase23.02.2017National basic fee paid 
23.02.2017Designation fee(s) paid 
23.02.2017Examination fee paid 
Examination procedure23.02.2017Examination requested  [2017/30]
23.02.2017Date on which the examining division has become responsible
29.09.2017Amendment by applicant (claims and/or description)
29.08.2018Despatch of a communication from the examining division (Time limit: M06)
15.03.2019Reply to a communication from the examining division
08.07.2019Invitation to indicate the basis for amendments (Time limit: M01)
12.08.2019Reply to an invitation to indicate the basis for amendments
14.11.2019Despatch of a communication from the examining division (Time limit: M02)
24.01.2020Reply to a communication from the examining division
26.10.2020Cancellation of oral proceeding that was planned for 23.11.2020
05.11.2020Despatch of communication that the application is refused, reason: substantive examination [2021/12]
15.11.2020Application refused, date of legal effect [2021/12]
23.11.2020Date of oral proceedings (cancelled)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
15.03.2019Request for further processing filed
15.03.2019Full payment received (date of receipt of payment)
Request granted
26.03.2019Decision despatched
Fees paidRenewal fee
31.08.2017Renewal fee patent year 03
31.08.2018Renewal fee patent year 04
02.09.2019Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.08.202006   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2013192165  (UNIV KANSAS [US], et al) [X] 1-11,13-19 * paragraphs [0014] - [0021] *;
 [XD]  - STOCKWELL SIMON R ET AL, "Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling.", PLOS ONE 2012, (2012), vol. 7, no. 1, ISSN 1932-6203, pages 1 - 16, XP002731158 [XD] 1-19 * page 12, column l, lines 55-64 *

DOI:   http://dx.doi.org/10.1371/journal.pone.0028568
 [X]  - LEE DO YEON ET AL, "Activation of PERK signaling attenuates Abeta-mediated ER stress.", PLOS ONE 2010, (2010), vol. 5, no. 5, ISSN 1932-6203, pages 1 - 8, XP002731159 [X] 1-11,13-19 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pone.0010489
Examination   - KOVACS ET AL., NERVENARZT, (20180817), vol. 89, pages 1083 - 1094
    - GÖTZ ET AL., ANNU. REV. PATHOL. MECH. DIS., (20181024), vol. 14, pages 239 - 261
    - WILLIAMS, INTERNAL MEDICINE JOURNAL, (2006), vol. 36, pages 652 - 660
by applicantWO2013192165
    - AXTEN, J. M. ET AL., J MED CHEM, (2012), vol. 55, no. 16, pages 7193 - 207
    - B'CHIR, W. ET AL., NUCLEIC ACIDS RES, (2013), vol. 41, no. 16, pages 7683 - 99
    - BOUMAN, L. ET AL., CELL DEATH DIFFER, (2011), vol. 18, no. 5, pages 769 - 82
    - BOYCE, M. ET AL., SCIENCE, (2005), vol. 307, no. 5711, pages 935 - 9
    - BOXER ET AL., LANCET NEUROL, (2014), vol. 13, no. 7, pages 676 - 85
    - BRUCH, J ET AL., J NEUROPATHOL EXP NEUROL., (2015), vol. 74, no. 8, pages 850 - 7
    - BUEE-SCHERRER, V. ET AL., BRAIN RES MOL BRAIN RES, (1996), vol. 39, no. 1-2, pages 79 - 88
    - CAILLIEREZ, R. ET AL., MOL THER, (2013), vol. 21, no. 7, pages 1358 - 68
    - CULLINAN, S. B. ET AL., MOL CELL BIOL, (2003), vol. 23, no. 20, pages 7198 - 209
    - ESCOBAR-KHONDIKER, M. ET AL., J NEUROSCI, (2007), vol. 27, no. 29, pages 7827 - 37
    - GANI, A. R. ET AL., ARCH BIOCHEM BIOPHVS, (2015), vol. 568, pages 8 - 15
    - GIBSON, D. G. ET AL., NAT METHODS, (2009), vol. 6, no. 5, pages 343 - 5
    - HETZ, C. ET AL., NAT REV NEUROSCI, (2014), vol. 15, no. 4, pages 233 - 49
    - HOGLINGER, G. U. ET AL., NAT GENET, (2011), vol. 43, no. 7, pages 699 - 705
    - ISHIZAWA, T. ET AL., J NEUROPATHOL EXP NEUROL, (2003), vol. 62, no. 4, pages 389 - 97
    - JICHA, G. A. ET AL., J NEUROSCI RES, (1997), vol. 48, no. 2, pages 128 - 32
    - KUHN, P. H. ET AL., EMBO J, (2010), vol. 29, no. 17, pages 3020 - 32
    - LEE DO, Y. ET AL., PLOS ONE, (2010), vol. 5, no. 5, page E10489
    - LIU, F. ET AL., MOL NEURODEQENER, (2008), vol. 3, page 8
    - LOEWEN, C. A ET AL., PLOS ONE, (2010), vol. 5, no. 9
    - LOTHARIUS, J. ET AL., J NEUROSCI, (2005), vol. 25, no. 27, pages 6329 - 42
    - MA, T. ET AL., NAT NEUROSCI, (2013), vol. 16, no. 9, pages 1299 - 305
    - MORENO, J. A. ET AL., SCI TRANSL MED, (2013), vol. 5, no. 206, page 206RA138
    - OZASA, R. ET AL., CELL STRUCT FUNCT, (2013), vol. 38, no. 2, pages 183 - 95
    - PYTEL, D. ET AL., J BIOMOL SCREEN, (2014), vol. 19, no. 7, pages 1024 - 34
    - SCHEPER, W. ET AL., SCI TRANSL MED, (2013), vol. 5, no. 206, page 206FS37
    - STOCKWELL, S. R. ET AL., PLOS ONE, (2012), vol. 7, no. 1, page E28568
    - STUTZBACH, L. D. ET AL., ACTA NEUROPATHOL COMMUN, (2013), vol. 1, page 31
    - TOLOSA ET AL., MOV DISORD., (2014), vol. 29, no. 4, pages 470 - 8
    - VACCARO, A. ET AL., NEUROBIOL DIS, (2013), vol. 55, pages 64 - 75
    - VAN DER HARG, J. M. ET AL., CELL DEATH DIS, (2014), vol. 5, page E1393
    - WIN, S. ET AL., J HEPATOL, (2015), vol. 62, no. 6, pages 1367 - 74
    - WU, H. L. ET AL., CARDIOVASC RES, (2009), vol. 81, no. 1, pages 148 - 58
    - XIE, W. ET AL., PLOS ONE, (2015), vol. 10, no. 3, page E0119738
    - XU, H. ET AL., NEUROPATHOL APPL NEUROBIOL, (2014), vol. 40, no. 7, pages 833 - 43
    - YAN, Y. ET AL., BMC CANCER, (2010), vol. 10, page 445
    - YANG, L. ET AL., J BIOL CHEM, (2013), vol. 288, no. 19, pages 13631 - 8
    - ZHU, Y. ET AL., J NEUROSCI, (2008), vol. 28, no. 9, pages 2168 - 78
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.